Therapeutic strategies in multiple system atrophy
Identifieur interne : 003706 ( Main/Exploration ); précédent : 003705; suivant : 003707Therapeutic strategies in multiple system atrophy
Auteurs : Gregor K. Wenning [Autriche] ; Felix Geser [Autriche] ; Werner Poewe [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-08.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adrenergic alpha-Antagonists (therapeutic use), Anti-Inflammatory Agents (therapeutic use), Anticonvulsants (therapeutic use), Autonomic Nervous System Diseases (therapy), Cholinergic Agents (therapeutic use), Dopamine Agonists (pharmacology), Dopamine Agonists (therapeutic use), Humans, Multiple System Atrophy (therapy), Multiple system atrophy, N-Methylaspartate (antagonists & inhibitors), Nervous system diseases, Palliative Care, Parkinsonian Disorders (therapy), Parkinsonism, Strategy, Treatment, dysautonomia, multiple system atrophy, therapy.
- MESH :
- chemical , antagonists & inhibitors : N-Methylaspartate.
- chemical , pharmacology : Dopamine Agonists.
- chemical , therapeutic use : Adrenergic alpha-Antagonists, Anti-Inflammatory Agents, Anticonvulsants, Cholinergic Agents, Dopamine Agonists.
- therapy : Autonomic Nervous System Diseases, Multiple System Atrophy, Parkinsonian Disorders.
- Humans, Palliative Care.
Abstract
This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with other warning features (red flags), and pathologically by cell loss, gliosis, and glial cytoplasmic inclusions in selected multiple regions of the brain and spinal cord. Because of the small number of randomized controlled trials, the management of MSA is largely based on empirical or open‐label evidence. Parkinsonism often shows a poor or unsustained response to chronic levodopa therapy, although more patients than previously recognized may experience an initial moderate‐to‐good dopaminergic response. There is no effective drug treatment for cerebellar ataxia. However, features of dysautonomia such as orthostatic hypotension, urinary retention or incontinence, constipation, and impotence, may often be relieved if recognized by the treating physician. Because no drug treatment consistently benefits patients with this disease in the long‐term, palliative therapies are all the more important. Novel symptomatic and neuroprotective therapies are urgently required. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20543
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000967
- to stream Istex, to step Curation: 000967
- to stream Istex, to step Checkpoint: 002112
- to stream PubMed, to step Corpus: 002F33
- to stream PubMed, to step Curation: 002F33
- to stream PubMed, to step Checkpoint: 002F38
- to stream Ncbi, to step Merge: 001379
- to stream Ncbi, to step Curation: 001379
- to stream Ncbi, to step Checkpoint: 001379
- to stream Main, to step Merge: 004D89
- to stream PascalFrancis, to step Corpus: 001D75
- to stream PascalFrancis, to step Curation: 000F46
- to stream PascalFrancis, to step Checkpoint: 001C93
- to stream Main, to step Merge: 005171
- to stream Main, to step Curation: 003706
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic strategies in multiple system atrophy</title><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name></author><author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:68ABAC9648F256FE23517D8A28A17EF15250C966</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20543</idno><idno type="url">https://api.istex.fr/document/68ABAC9648F256FE23517D8A28A17EF15250C966/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000967</idno><idno type="wicri:Area/Istex/Curation">000967</idno><idno type="wicri:Area/Istex/Checkpoint">002112</idno><idno type="wicri:doubleKey">0885-3185:2005:Wenning G:therapeutic:strategies:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16092094</idno><idno type="wicri:Area/PubMed/Corpus">002F33</idno><idno type="wicri:Area/PubMed/Curation">002F33</idno><idno type="wicri:Area/PubMed/Checkpoint">002F38</idno><idno type="wicri:Area/Ncbi/Merge">001379</idno><idno type="wicri:Area/Ncbi/Curation">001379</idno><idno type="wicri:Area/Ncbi/Checkpoint">001379</idno><idno type="wicri:doubleKey">0885-3185:2005:Wenning G:therapeutic:strategies:in</idno><idno type="wicri:Area/Main/Merge">004D89</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0457535</idno><idno type="wicri:Area/PascalFrancis/Corpus">001D75</idno><idno type="wicri:Area/PascalFrancis/Curation">000F46</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001C93</idno><idno type="wicri:doubleKey">0885-3185:2005:Wenning G:therapeutic:strategies:in</idno><idno type="wicri:Area/Main/Merge">005171</idno><idno type="wicri:Area/Main/Curation">003706</idno><idno type="wicri:Area/Main/Exploration">003706</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic strategies in multiple system atrophy</title><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Innsbruck Medical University, Clinical Department of Neurology</wicri:regionArea><wicri:noRegion>Clinical Department of Neurology</wicri:noRegion></affiliation></author><author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Innsbruck Medical University, Clinical Department of Neurology</wicri:regionArea><wicri:noRegion>Clinical Department of Neurology</wicri:noRegion></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Innsbruck Medical University, Clinical Department of Neurology</wicri:regionArea><wicri:noRegion>Clinical Department of Neurology</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08">2005-08</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S12</biblScope><biblScope unit="supplement">S12</biblScope><biblScope unit="page" from="S67">S67</biblScope><biblScope unit="page" to="S76">S76</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">68ABAC9648F256FE23517D8A28A17EF15250C966</idno><idno type="DOI">10.1002/mds.20543</idno><idno type="ArticleID">MDS20543</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic alpha-Antagonists (therapeutic use)</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Anticonvulsants (therapeutic use)</term><term>Autonomic Nervous System Diseases (therapy)</term><term>Cholinergic Agents (therapeutic use)</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine Agonists (therapeutic use)</term><term>Humans</term><term>Multiple System Atrophy (therapy)</term><term>Multiple system atrophy</term><term>N-Methylaspartate (antagonists & inhibitors)</term><term>Nervous system diseases</term><term>Palliative Care</term><term>Parkinsonian Disorders (therapy)</term><term>Parkinsonism</term><term>Strategy</term><term>Treatment</term><term>dysautonomia</term><term>multiple system atrophy</term><term>therapy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>N-Methylaspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic alpha-Antagonists</term><term>Anti-Inflammatory Agents</term><term>Anticonvulsants</term><term>Cholinergic Agents</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Palliative Care</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Atrophie multisystématisée</term><term>Parkinsonisme</term><term>Stratégie</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with other warning features (red flags), and pathologically by cell loss, gliosis, and glial cytoplasmic inclusions in selected multiple regions of the brain and spinal cord. Because of the small number of randomized controlled trials, the management of MSA is largely based on empirical or open‐label evidence. Parkinsonism often shows a poor or unsustained response to chronic levodopa therapy, although more patients than previously recognized may experience an initial moderate‐to‐good dopaminergic response. There is no effective drug treatment for cerebellar ataxia. However, features of dysautonomia such as orthostatic hypotension, urinary retention or incontinence, constipation, and impotence, may often be relieved if recognized by the treating physician. Because no drug treatment consistently benefits patients with this disease in the long‐term, palliative therapies are all the more important. Novel symptomatic and neuroprotective therapies are urgently required. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li></country><region><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Autriche"><noRegion><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name></noRegion><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003706 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003706 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:68ABAC9648F256FE23517D8A28A17EF15250C966
|texte= Therapeutic strategies in multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23. |  |